NYSE:BMY
Bristol Myers Squibb (BMY)
Financials 
Technical Analysis 
Aug 9, 2026, 12:00 amThis summary was created by AI, based on 8 opinions in the last 12 months.
Bristol Myers Squibb (BMY) has received mixed reviews from various experts, reflecting a combination of cautious optimism and disappointment regarding its drug pipeline and overall performance. Highlighted is the stock's impressive +19% growth this year, alongside its strong cash flow generation expected to reach $11 billion this year and $15 billion by 2027, all while offering a substantial dividend yield over 4%. However, concerns have been raised about the underwhelming sales performance of the Cobenfy drug, with some experts recommending a more cautious approach as they await positive news regarding its prospects. Overall, the company’s recent earnings performance surpassed expectations, showcasing a solid 3% sales growth and a promising outlook for its growth portfolio, which could help restore investor confidence if it continues to outperform legacy offerings.
EPS of $1.63 beat estimates of $1.52 and sales of $12.2B beat estimates of $11.8B. Sales grew 3%, and management raised its 2025 revenue guidance to a range of $47.5B to $48.0B. Its growth portfolio sales of newer/higher-growth drugs were up 18% year-over-year, while its legacy portfolio sales were down 12%. These were decent results, and the price action looks decent, we think there is possibility that the name can rebound eventually if its growth portfolio continues to outpace its legacy portfolio.
Unlock Premium - Try 5i Free
EPS of $1.63 beat estimates of $1.52 and sales of $12.2B beat estimates of $11.8B. Sales grew 3%, and management raised its 2025 revenue guidance to a range of $47.5B to $48.0B. Its growth portfolio sales of newer/higher-growth drugs were up 18% year-over-year, while its legacy portfolio sales were down 12%. These were decent results, and the price action looks decent, we think there is possibility that the name can rebound eventually if its growth portfolio continues to outpace its legacy portfolio.
Unlock Premium - Try 5i Free
EPS of $1.63 beat estimates of $1.52 and sales of $12.2B beat estimates of $11.8B. Sales grew 3%, and management raised its 2025 revenue guidance to a range of $47.5B to $48.0B. Its growth portfolio sales of newer/higher-growth drugs were up 18% year-over-year, while its legacy portfolio sales were down 12%. These were decent results, and the price action looks decent, we think there is possibility that the name can rebound eventually if its growth portfolio continues to outpace its legacy portfolio.
Unlock Premium - Try 5i Free
EPS of $1.63 beat estimates of $1.52 and sales of $12.2B beat estimates of $11.8B. Sales grew 3%, and management raised its 2025 revenue guidance to a range of $47.5B to $48.0B. Its growth portfolio sales of newer/higher-growth drugs were up 18% year-over-year, while its legacy portfolio sales were down 12%. These were decent results, and the price action looks decent, we think there is possibility that the name can rebound eventually if its growth portfolio continues to outpace its legacy portfolio.
Unlock Premium - Try 5i Free
They have huge oncology franchise, but face a huge patent cliff. But they have a some promising drugs. He owns this partly for the 5.6% dividend. He took shares off the table when the stock spiked earlier this year, but at current levels, he's watching the price go lower before buying again.
It's turned around in the last 6 months under the new CEO, rallying 40%. In the face of expiring drug patents, they launched a revolutionary schizophrenia drug. He also likes the rest of their pipeline to treat cardiovascular disease and oncology. He bought shares late last year.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Popular Articles
Bristol Myers Squibb (BMY) Frequently Asked Questions
What is Bristol Myers Squibb stock symbol?
Bristol Myers Squibb is a American stock, trading under the symbol BMY (previously BMY-N on Stockchase) on the New York Stock Exchange (BMY). It is usually referred to as NYSE:BMY or BMY
Is Bristol Myers Squibb a buy or a sell?
In the last year, 8 stock analysts issued a Buy, Sell, or Hold rating on BMY (previously BMY-N on Stockchase). 2 analysts recommended to BUY and 2 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Bristol Myers Squibb.
Is Bristol Myers Squibb a good investment or a top pick?
Bristol Myers Squibb was recommended as a Top Pick by Jenny Harrington, CEO, Gilman Hill Asset Management on 2026-08-07. Read the latest stock experts ratings for Bristol Myers Squibb.
Why is Bristol Myers Squibb stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Bristol Myers Squibb.
Is Bristol Myers Squibb worth watching?
Bristol Myers Squibb is followed by 160 investors on Stockchase and is a trending stock that is worth watching.
What is Bristol Myers Squibb stock price?
On 2026-08-07, Bristol Myers Squibb (BMY) stock closed at a price of $64.72.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
'%20fill='%23EAEAEA'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M131.499729,2.82302245e-05%20C132.285413,-0.00432461793%20133.254164,0.496634241%20133.645655,1.25173399%20L133.712109,1.39623206%20L135.747863,6.45331817%20L141.028779,6.80428588%20C141.60867,6.84282525%20142.147242,7.1236355%20142.517275,7.58038413%20C143.223405,8.45199453%20143.142035,9.72214747%20142.357105,10.4940033%20L142.234099,10.6059323%20L138.072656,14.10894%20L139.356339,19.592529%20C139.472157,20.0872738%20139.394126,20.6085551%20139.13883,21.0455786%20C138.624329,21.9263208%20137.536956,22.2447485%20136.649713,21.8010736%20L136.511398,21.7246573%20L131.5,18.7715858%20L126.488602,21.7246573%20C125.579092,22.2767096%20124.40275,21.9726757%20123.86117,21.0455786%20C123.605874,20.6085551%20123.527843,20.0872738%20123.643661,19.592529%20L124.927344,14.10894%20L120.765901,10.6059323%20C119.868071,9.85015912%20119.741289,8.49557505%20120.482725,7.58038413%20C120.852758,7.1236355%20121.39133,6.84282525%20121.971221,6.80428588%20L127.252137,6.45331817%20L129.287891,1.39623206%20C129.624025,0.561228427%20130.665516,-0.00460395016%20131.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-8'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
She hopes healthcare stocks rebound; they've been up this year and being beaten down for a long time. BMY is +19% this year. Trades below 10x PE and produce $11 billion free cash flow this year, $15 billion in 2027, pays over a 4% dividend. There's value here. With their cash flow, they can buy their way to growth.